Literature DB >> 24570104

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab.

Vittorio Fusco1, Alberto Bedogni, Giuseppina Campisi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24570104     DOI： 10.1007/s00520-014-2159-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  10 in total

1.  Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.

Authors:  Géraldine Lescaille; Amélie E Coudert; Vanessa Baaroun; Agnès Ostertag; Emmanuel Charpentier; Marie-José Javelot; Rafael Tolédo; Patrick Goudot; Jean Azérad; Ariane Berdal; Jean-Philippe Spano; Blandine Ruhin; Vianney Descroix
Journal:  Bone       Date:  2013-10-09       Impact factor: 4.398

2.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

4.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

Review 5.  Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Authors:  Matthias Troeltzsch; Timothy Woodlock; Stefanie Kriegelstein; Timm Steiner; Karl Messlinger; Markus Troeltzsch
Journal:  J Can Dent Assoc       Date:  2012       Impact factor: 1.316

6.  Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?

Authors:  Peter Johannes Hansen; Michael Knitschke; Florian Guy Draenert; Sebastian Irle; Andreas Neff
Journal:  Clin Oral Investig       Date:  2012-11-01       Impact factor: 3.573

7.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Authors:  David Henry; Saroj Vadhan-Raj; Vera Hirsh; Roger von Moos; Vania Hungria; Luis Costa; Penella J Woll; Giorgio Scagliotti; Geoffrey Smith; Amy Feng; Susie Jun; Roger Dansey; Howard Yeh
Journal:  Support Care Cancer       Date:  2013-10-26       Impact factor: 3.603

8.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Authors:  Allan Lipton; Karim Fizazi; Alison T Stopeck; David H Henry; Janet E Brown; Denise A Yardley; Gary E Richardson; Salvatore Siena; Pablo Maroto; Michael Clemens; Boris Bilynskyy; Veena Charu; Philippe Beuzeboc; Michael Rader; Maria Viniegra; Fred Saad; Chunlei Ke; Ada Braun; Susie Jun
Journal:  Eur J Cancer       Date:  2012-09-10       Impact factor: 9.162

9.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

10.  Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Authors:  B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski
Journal:  Br J Cancer       Date:  2012-11-06       Impact factor: 7.640
  10 in total
  1 in total

1.  Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?

Authors:  Giacomo Oteri; Giuseppina Campisi; Vera Panzarella; Ilaria Morreale; Riccardo Nucera; Olga Di Fede; Antonio Picone; Antonia Marcianò
Journal:  Biomed Res Int       Date:  2018-05-29       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.